Department of Breast, School of Medicine, The International Peace Maternity and Child Health Hospital, Shanghai Jiao Tong University, Shanghai, China.
Shanghai Key Laboratory of Embryo Original Diseases, Shanghai, China.
J Clin Lab Anal. 2021 Sep;35(9):e23952. doi: 10.1002/jcla.23952. Epub 2021 Aug 17.
Increasing studies reported that long non-coding RNAs are involved in regulating breast cancer (BRCA) progression. However, the specific roles and mechanisms of lncRNAs in BRCA remain largely unknown. Here, we sought to explore the functions and mechanisms of AC016405.3 in BRCA progression.
Bioinformatic analysis for AC016405.3, miR-22-3p, and ERBB3 were performed on starBase. The expressions of AC016405.3, miR-22-3p, and ERBB3 were examined by RT-qPCR. The functions of AC016405.3 on the proliferation, migration, and invasion of cells were evaluated by conducting CCK-8, colony formation, wound-healing, and Transwell assays. The subcellular distribution of AC016405.3 in BRCA cells was identified by performing fluorescence in situ hybridization (FISH) and subcellular fractionation techniques. Dual-luciferase assay was applied to validate the interactions of miR-22-3p with AC016405.3 or ERBB3. The interaction between ERBB3 and miR-22-3p was also tested by Anti-Ago2 RNA immunoprecipitation (RIP) assay.
The results showed that AC016405.3 is highly expressed in BRCA tissues as well as cells and positively correlated with poor prognosis in BRCA patients. Silencing AC016405.3 obviously repressed the malignant behaviors of BRCA cells. Mechanistically, AC016405.3 functioned as a competing endogenous RNA (ceRNA) for miR-22-3p in the cytoplasm and sponged miR-22-3p to release its suppression of ERBB3. Rescue experiments revealed that the suppression role induced by AC016405.3 depletion on malignant behaviors of BRCA cells could be obviously counter by inhibiting miR-22-3p or overexpressing ERBB3.
AC016405.3 promotes BRCA progression by the derepression of ERBB3 via sponging miR-22-3p, which may represent a potential target for BRCA treatment.
越来越多的研究表明,长非编码 RNA 参与调节乳腺癌(BRCA)的进展。然而,lncRNAs 在 BRCA 中的具体作用和机制在很大程度上仍然未知。在这里,我们试图探讨 AC016405.3 在 BRCA 进展中的功能和机制。
通过 starBase 对 AC016405.3、miR-22-3p 和 ERBB3 进行生物信息学分析。通过 RT-qPCR 检测 AC016405.3、miR-22-3p 和 ERBB3 的表达。通过 CCK-8、集落形成、划痕愈合和 Transwell 实验评估 AC016405.3 对细胞增殖、迁移和侵袭的功能。通过荧光原位杂交(FISH)和亚细胞分离技术鉴定 BRCA 细胞中 AC016405.3 的亚细胞分布。通过双荧光素酶报告基因实验验证 miR-22-3p 与 AC016405.3 或 ERBB3 的相互作用。通过 Anti-Ago2 RNA 免疫沉淀(RIP)实验测试 ERBB3 和 miR-22-3p 之间的相互作用。
结果表明,AC016405.3 在 BRCA 组织和细胞中高表达,并与 BRCA 患者的不良预后呈正相关。沉默 AC016405.3 明显抑制 BRCA 细胞的恶性行为。机制上,AC016405.3 在细胞质中作为 miR-22-3p 的竞争性内源 RNA(ceRNA)发挥作用,并通过海绵吸附 miR-22-3p 来释放其对 ERBB3 的抑制作用。挽救实验表明,AC016405.3 耗竭对 BRCA 细胞恶性行为的抑制作用可通过抑制 miR-22-3p 或过表达 ERBB3 明显逆转。
AC016405.3 通过海绵吸附 miR-22-3p 来解除 ERBB3 的抑制作用,从而促进 BRCA 的进展,这可能代表 BRCA 治疗的一个潜在靶点。